Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.

Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, Segal N, Gregor P, Engelhorn M, Riviere I, Houghton AN, Wolchok JD.

Clin Cancer Res. 2003 Apr;9(4):1284-90.

2.

Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center.

Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE, Gregor P, Houghton AN, Perales MA, Wolchok JD.

Vaccine. 2006 May 22;24(21):4582-5. Epub 2005 Aug 24.

PMID:
16188351
3.

Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor.

Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S, Hess PR, Jankowski MK, Jones PD, Leibman NF, Johnson MH, Kurzman ID, Wolchok JD.

Am J Vet Res. 2011 Dec;72(12):1631-8. doi: 10.2460/ajvr.72.12.1631.

PMID:
22126691
4.

Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs.

Manley CA, Leibman NF, Wolchok JD, Rivière IC, Bartido S, Craft DM, Bergman PJ.

J Vet Intern Med. 2011 Jan-Feb;25(1):94-9. doi: 10.1111/j.1939-1676.2010.0627.x. Epub 2010 Dec 8.

5.

Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.

Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, Miles S, Liu X, Obrocea M, Qiu Z, Bot A.

J Immunother. 2008 Feb-Mar;31(2):215-23. doi: 10.1097/CJI.0b013e3181611420.

PMID:
18481391
6.

Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.

Di Nicola M, Carlo-Stella C, Mortarini R, Baldassari P, Guidetti A, Gallino GF, Del Vecchio M, Ravagnani F, Magni M, Chaplin P, Cascinelli N, Parmiani G, Gianni AM, Anichini A.

Clin Cancer Res. 2004 Aug 15;10(16):5381-90.

7.

Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles.

Goldberg SM, Bartido SM, Gardner JP, Guevara-Patiño JA, Montgomery SC, Perales MA, Maughan MF, Dempsey J, Donovan GP, Olson WC, Houghton AN, Wolchok JD.

Clin Cancer Res. 2005 Nov 15;11(22):8114-21.

8.

Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.

Scheibenbogen C, Schmittel A, Keilholz U, Allgäuer T, Hofmann U, Max R, Thiel E, Schadendorf D.

J Immunother. 2000 Mar-Apr;23(2):275-81. Erratum in: J Immunother 2000 Jul-Aug;23(4):509.

PMID:
10746554
9.

Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma.

Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS.

Cancer. 2003 Jul 1;98(1):144-54.

10.

A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).

Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, Weigle B, Schmitz M, Mateo L, Schmidt B, Bernhard H, Jakob T, Hein R, Schuler G, Schuler-Thurner B, Wagner SN, Drexler I, Sutter G, Arndtz N, Chaplin P, Metz J, Enk A, Huber C, Wölfel T.

Cancer Immunol Immunother. 2005 May;54(5):453-67. Epub 2004 Dec 31.

PMID:
15627214
11.

Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma.

Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, Houghton AN, Bergman PJ.

Cancer Immun. 2006 Apr 21;6:8.

12.

Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma.

Alexander AN, Huelsmeyer MK, Mitzey A, Dubielzig RR, Kurzman ID, Macewen EG, Vail DM.

Cancer Immunol Immunother. 2006 Apr;55(4):433-42. Epub 2005 Jun 18.

PMID:
15965647
13.
14.

Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.

MacEwen EG, Kurzman ID, Vail DM, Dubielzig RR, Everlith K, Madewell BR, Rodriguez CO Jr, Phillips B, Zwahlen CH, Obradovich J, Rosenthal RC, Fox LE, Rosenberg M, Henry C, Fidel J.

Clin Cancer Res. 1999 Dec;5(12):4249-58.

15.

Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients.

Quaglino P, Osella-Abate S, Cappello N, Ortoncelli M, Nardò T, Fierro MT, Cavallo F, Savoia P, Bernengo MG.

Melanoma Res. 2007 Apr;17(2):75-82.

PMID:
17496782
16.

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J.

J Clin Oncol. 2005 Dec 10;23(35):8968-77. Epub 2005 Oct 3.

PMID:
16204013
17.

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.

Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, Vernel-Pauillac F, Boyer A, Baron-Bodo V, Mallard E, Bartholeyns J, Goxe B, Latour N, Leroy S, Prigent D, Martiat P, Sales F, Laporte M, Bruyns C, Romet-Lemonne JL, Abastado JP, Lehmann F, Velu T.

Cancer Immunol Immunother. 2006 Jul;55(7):819-29. Epub 2005 Sep 27.

PMID:
16187085
18.

Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.

Stopeck AT, Jones A, Hersh EM, Thompson JA, Finucane DM, Gutheil JC, Gonzalez R.

Clin Cancer Res. 2001 Aug;7(8):2285-91.

19.

Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.

Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC.

J Clin Oncol. 2005 Dec 10;23(35):8978-91. Epub 2005 Oct 31.

PMID:
16260696
20.

Supplemental Content

Support Center